查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1611860

万古霉素市场：按类型、剂型、给药途径、应用、分销管道 - 全球预测 2025-2030

Vancomycin Market by Type (Ampicillin, Chloramphenicol, Daptomycin), Form (Capsule, Oral Solution (Liquid), Powder), Route of Administration, Application, Distribution Channel - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年万古霉素市值为6.9323亿美元，预计2024年将达到7.4153亿美元，复合年增长率为5.26%，预计到2030年将达到9.9287亿美元。

万古霉素是一种强效抗生素，主要用于治疗严重的细菌感染疾病，特别是对其他抗生素抗药性的革兰氏阳性菌感染疾病，例如抗药性金黄色葡萄球菌(MRSA)。作为360iResearch的市场研究分析师，有必要认识到它对于治疗细菌性心内膜炎和骨髓炎等危及生命的疾病是必要的。应用范围遍及医疗机构，包括医院、诊所和专科医疗单位，并针对需要静脉给药的严重感染疾病患者。最终用途领域包括医疗保健提供者、製药公司、研究机构等。抗生素抗药性感染疾病的增加、抗菌药物管理意识的增强以及药物开发技术的进步推动了市场的发展。对有效治疗通讯协定的需求也不断增长，以解决门诊和住院环境中的慢性和急性感染疾病。主要商机包括开发提高万古霉素功效的製剂，包括组合疗法和新型药物输送系统，例如靶向奈米载体。对市场相关人员的建议包括投资此类研发以及探索与生技公司的合作。挑战包括万古霉素的潜在副作用，例如肾毒性，以及由于抗药性细菌的增加而需要继续开发新的抗生素。医药品认证过程中的监管障碍也对市场扩张构成了障碍。创新机会包括开发新的协同效应製剂、优化剂量策略以尽量减少副作用，以及开发快速诊断方法以更精确地客製化万古霉素治疗。万古霉素市场竞争激烈，相关人员必须优先考虑策略伙伴关係和产品创新，才能在不断增长但严格监管的市场中保持竞争力。解决这些因素将有助于维持成长并有效扩大市场范围。

主要市场统计
基准年[2023] 6.9323 亿美元
预计年份 [2024] 74153万美元
预测年份 [2030] 99287万美元
复合年增长率（%） 5.26%

市场动态：揭示快速发展的万古霉素市场的关键市场洞察

万古霉素市场正因供需的动态交互作用而转变。了解这些不断变化的市场动态可以帮助企业做出明智的投资决策、策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 全球细菌感染疾病流行不断扩大
    • 政府的感染控制优势策略
    • 对学名药的需求不断增长
  • 市场限制因素
    • 万古霉素对健康的不良影响
  • 市场机会
    • 优化万古霉素剂量的创新方法
    • 正确使用万古霉素的有前途的教育倡议
  • 市场挑战
    • 万古霉素替代品的存在

波特的五力：驾驭万古霉素市场的策略工具

波特的五力架构是了解万古霉素市场竞争格局的关键工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解万古霉素市场的外部影响

外部宏观环境因素对万古霉素市场表现动态起着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解万古霉素市场竞争状况

万古霉素市场的详细市场占有率分析可以对供应商的绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵万古霉素市场供应商的绩效评估

FPNV定位矩阵是评估万古霉素市场供应商的重要工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，以确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析和建议描绘了万古霉素市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，万古霉素市场的策略分析至关重要。透过考虑关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 世界各地细菌感染疾病的盛行率增加
      • 政府首选的感染控制策略
      • 对非专利替代品的需求不断增长
    • 抑制因素
      • 万古霉素对健康的不良影响
    • 机会
      • 优化万古霉素输送的创新方法
      • 为正确使用万古霉素而进行的教育工作有希望
    • 任务
      • 万古霉素的潜在替代品的存在
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章万古霉素市场：依类型

  • Ampicillin
  • 氯霉素
  • Daptomycin
  • Linezolid
  • 奎奴普丁

第七章 万古霉素市场：依形式

  • 胶囊
  • 口服溶液（液体）
  • 粉末

第八章万古霉素市场：依给药途径

  • 静脉
  • 口服

第九章万古霉素市场：依应用分类

  • 结肠炎和肠道发炎
  • 肺部感染疾病
  • 败血症
  • 皮肤和软组织感染疾病

第10章万古霉素市场：依分销管道划分

  • 门诊药房
  • 医院药房
  • 网路药房

第十一章 美洲万古霉素市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十二章 亚太地区万古霉素市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十三章 欧洲、中东、非洲万古霉素市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第14章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • Alvogen
  • Aphios Corporation
  • CJ CheilJedang Corporation
  • Eli Lilly and Company
  • Enanta Pharmaceuticals, Inc.
  • GlaxoSmithKline PLC
  • Helix BioMedix, Inc.
  • Innovation Pharmaceuticals Inc.
  • LegoChem Biosciences, Inc.
  • Lytix Biopharma AS
  • MGB Biopharma
  • Microbiotix, Inc.
  • MicuRx Pharmaceuticals
  • Nabriva Therapeutics GmbH
  • North China Pharmaceutical Group Co., Ltd.
  • NovaBay Pharmaceuticals, Inc.
  • NovoBiotic Pharmaceuticals, LLC
  • Oragenics, Inc.
  • Pfizer Inc.
  • Sanofi SA
  • Sealife Pharma GmbH
  • VIANEX
  • Xellia Pharmaceuticals ApS
  • Zealand Pharma A/S
  • Zhejiang Hisun Pharmaceutical Co., Ltd.
  • Zhejiang Pharmaceutical Co., Ltd.
Product Code: MRR-C002B1C99629

The Vancomycin Market was valued at USD 693.23 million in 2023, expected to reach USD 741.53 million in 2024, and is projected to grow at a CAGR of 5.26%, to USD 992.87 million by 2030.

Vancomycin is a potent antibiotic primarily used to treat severe bacterial infections, especially those caused by Gram-positive bacteria resistant to other antibiotics, such as Methicillin-resistant Staphylococcus aureus (MRSA). As a market research analyst at 360iResearch, it's vital to recognize its necessity for treating life-threatening conditions like bacterial endocarditis and osteomyelitis. The application scope extends across healthcare settings, including hospitals, clinics, and specialized healthcare units, targeting patients with serious infections that necessitate intravenous drug delivery. End-use segments include healthcare providers, pharmaceutical companies, and research institutes. The market is fueled by the increasing prevalence of antibiotic-resistant infections, growing awareness of antimicrobial stewardship, and advancements in drug development technologies. There is also rising demand for efficient treatment protocols to combat chronic and acute infections in outpatient and inpatient settings. Key opportunities include developing formulations that enhance vancomycin's efficacy, such as combinatorial therapies and novel drug delivery systems like targeted nanocarriers. Recommendations for market players involve investing in such R&D and exploring collaborations with biotechnology firms. Challenges include vancomycin's potential side effects, such as nephrotoxicity, and the rising bacterial resistance to its use, which necessitates the continuous development of novel antibiotics. Regulatory hurdles in drug approval processes also pose a barrier to market expansion. Innovation opportunities lie in creating new synergistic formulations, optimizing dosing strategies to minimize side effects, and developing rapid diagnostics to tailor vancomycin therapy more precisely. The nature of the vancomycin market is highly competitive and requires stakeholders to prioritize strategic partnerships and product innovation to maintain competitive edges in a market that is both growing but tightly monitored by regulatory agencies. Addressing these factors can help in sustaining growth and expanding market reach effectively.

KEY MARKET STATISTICS
Base Year [2023] USD 693.23 million
Estimated Year [2024] USD 741.53 million
Forecast Year [2030] USD 992.87 million
CAGR (%) 5.26%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Vancomycin Market

The Vancomycin Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Growing prevalence of bacterial infections across the globe
    • Favorable government strategies for infection control
    • Rising need for generic alternatives
  • Market Restraints
    • Adverse health impacts of vancomycin
  • Market Opportunities
    • Innovative approaches to optimize the delivery of vancomycin
    • Promising educational initiatives for adequate vancomycin use
  • Market Challenges
    • Presence of alternative substitutes of vancomycin

Porter's Five Forces: A Strategic Tool for Navigating the Vancomycin Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Vancomycin Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Vancomycin Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Vancomycin Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Vancomycin Market

A detailed market share analysis in the Vancomycin Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Vancomycin Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Vancomycin Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Vancomycin Market

A strategic analysis of the Vancomycin Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Vancomycin Market, highlighting leading vendors and their innovative profiles. These include Alvogen, Aphios Corporation, CJ CheilJedang Corporation, Eli Lilly and Company, Enanta Pharmaceuticals, Inc., GlaxoSmithKline PLC, Helix BioMedix, Inc., Innovation Pharmaceuticals Inc., LegoChem Biosciences, Inc., Lytix Biopharma AS, MGB Biopharma, Microbiotix, Inc., MicuRx Pharmaceuticals, Nabriva Therapeutics GmbH, North China Pharmaceutical Group Co., Ltd., NovaBay Pharmaceuticals, Inc., NovoBiotic Pharmaceuticals, LLC, Oragenics, Inc., Pfizer Inc., Sanofi SA, Sealife Pharma GmbH, VIANEX, Xellia Pharmaceuticals ApS, Zealand Pharma A/S, Zhejiang Hisun Pharmaceutical Co., Ltd., and Zhejiang Pharmaceutical Co., Ltd..

Market Segmentation & Coverage

This research report categorizes the Vancomycin Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Ampicillin, Chloramphenicol, Daptomycin, Linezolid, and Quinupristin.
  • Based on Form, market is studied across Capsule, Oral Solution (Liquid), and Powder.
  • Based on Route of Administration, market is studied across Intravenous and Oral.
  • Based on Application, market is studied across Colitis & Intestinal Inflammation, Lung Infection, Sepsis, and Skin Soft Tissue Infection.
  • Based on Distribution Channel, market is studied across Ambulatory Pharmacy, Hospital Pharmacy, and Online Pharmacy.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing prevalence of bacterial infections across the globe
      • 5.1.1.2. Favorable government strategies for infection control
      • 5.1.1.3. Rising need for generic alternatives
    • 5.1.2. Restraints
      • 5.1.2.1. Adverse health impacts of vancomycin
    • 5.1.3. Opportunities
      • 5.1.3.1. Innovative approaches to optimize the delivery of vancomycin
      • 5.1.3.2. Promising educational initiatives for adequate vancomycin use
    • 5.1.4. Challenges
      • 5.1.4.1. Presence of alternative substitutes of vancomycin
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Vancomycin Market, by Type

  • 6.1. Introduction
  • 6.2. Ampicillin
  • 6.3. Chloramphenicol
  • 6.4. Daptomycin
  • 6.5. Linezolid
  • 6.6. Quinupristin

7. Vancomycin Market, by Form

  • 7.1. Introduction
  • 7.2. Capsule
  • 7.3. Oral Solution (Liquid)
  • 7.4. Powder

8. Vancomycin Market, by Route of Administration

  • 8.1. Introduction
  • 8.2. Intravenous
  • 8.3. Oral

9. Vancomycin Market, by Application

  • 9.1. Introduction
  • 9.2. Colitis & Intestinal Inflammation
  • 9.3. Lung Infection
  • 9.4. Sepsis
  • 9.5. Skin Soft Tissue Infection

10. Vancomycin Market, by Distribution Channel

  • 10.1. Introduction
  • 10.2. Ambulatory Pharmacy
  • 10.3. Hospital Pharmacy
  • 10.4. Online Pharmacy

11. Americas Vancomycin Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Vancomycin Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Vancomycin Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
  • 14.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Alvogen
  • 2. Aphios Corporation
  • 3. CJ CheilJedang Corporation
  • 4. Eli Lilly and Company
  • 5. Enanta Pharmaceuticals, Inc.
  • 6. GlaxoSmithKline PLC
  • 7. Helix BioMedix, Inc.
  • 8. Innovation Pharmaceuticals Inc.
  • 9. LegoChem Biosciences, Inc.
  • 10. Lytix Biopharma AS
  • 11. MGB Biopharma
  • 12. Microbiotix, Inc.
  • 13. MicuRx Pharmaceuticals
  • 14. Nabriva Therapeutics GmbH
  • 15. North China Pharmaceutical Group Co., Ltd.
  • 16. NovaBay Pharmaceuticals, Inc.
  • 17. NovoBiotic Pharmaceuticals, LLC
  • 18. Oragenics, Inc.
  • 19. Pfizer Inc.
  • 20. Sanofi SA
  • 21. Sealife Pharma GmbH
  • 22. VIANEX
  • 23. Xellia Pharmaceuticals ApS
  • 24. Zealand Pharma A/S
  • 25. Zhejiang Hisun Pharmaceutical Co., Ltd.
  • 26. Zhejiang Pharmaceutical Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. VANCOMYCIN MARKET RESEARCH PROCESS
  • FIGURE 2. VANCOMYCIN MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL VANCOMYCIN MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL VANCOMYCIN MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL VANCOMYCIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL VANCOMYCIN MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL VANCOMYCIN MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL VANCOMYCIN MARKET SIZE, BY FORM, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL VANCOMYCIN MARKET SIZE, BY FORM, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL VANCOMYCIN MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL VANCOMYCIN MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. AMERICAS VANCOMYCIN MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. AMERICAS VANCOMYCIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. UNITED STATES VANCOMYCIN MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 19. UNITED STATES VANCOMYCIN MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC VANCOMYCIN MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. ASIA-PACIFIC VANCOMYCIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA VANCOMYCIN MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA VANCOMYCIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. VANCOMYCIN MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 25. VANCOMYCIN MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. VANCOMYCIN MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL VANCOMYCIN MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL VANCOMYCIN MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL VANCOMYCIN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. VANCOMYCIN MARKET DYNAMICS
  • TABLE 7. GLOBAL VANCOMYCIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL VANCOMYCIN MARKET SIZE, BY AMPICILLIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL VANCOMYCIN MARKET SIZE, BY CHLORAMPHENICOL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL VANCOMYCIN MARKET SIZE, BY DAPTOMYCIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL VANCOMYCIN MARKET SIZE, BY LINEZOLID, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL VANCOMYCIN MARKET SIZE, BY QUINUPRISTIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL VANCOMYCIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL VANCOMYCIN MARKET SIZE, BY CAPSULE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL VANCOMYCIN MARKET SIZE, BY ORAL SOLUTION (LIQUID), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL VANCOMYCIN MARKET SIZE, BY POWDER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL VANCOMYCIN MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL VANCOMYCIN MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL VANCOMYCIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL VANCOMYCIN MARKET SIZE, BY COLITIS & INTESTINAL INFLAMMATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL VANCOMYCIN MARKET SIZE, BY LUNG INFECTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL VANCOMYCIN MARKET SIZE, BY SEPSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL VANCOMYCIN MARKET SIZE, BY SKIN SOFT TISSUE INFECTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL VANCOMYCIN MARKET SIZE, BY AMBULATORY PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL VANCOMYCIN MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL VANCOMYCIN MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS VANCOMYCIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS VANCOMYCIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 32. AMERICAS VANCOMYCIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 33. AMERICAS VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 34. AMERICAS VANCOMYCIN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 35. ARGENTINA VANCOMYCIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. ARGENTINA VANCOMYCIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 37. ARGENTINA VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 38. ARGENTINA VANCOMYCIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 39. ARGENTINA VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 40. BRAZIL VANCOMYCIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. BRAZIL VANCOMYCIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 42. BRAZIL VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 43. BRAZIL VANCOMYCIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 44. BRAZIL VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 45. CANADA VANCOMYCIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. CANADA VANCOMYCIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 47. CANADA VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 48. CANADA VANCOMYCIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 49. CANADA VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 50. MEXICO VANCOMYCIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. MEXICO VANCOMYCIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 52. MEXICO VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 53. MEXICO VANCOMYCIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 54. MEXICO VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 55. UNITED STATES VANCOMYCIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. UNITED STATES VANCOMYCIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 57. UNITED STATES VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 58. UNITED STATES VANCOMYCIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 59. UNITED STATES VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 60. UNITED STATES VANCOMYCIN MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 61. ASIA-PACIFIC VANCOMYCIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. ASIA-PACIFIC VANCOMYCIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 63. ASIA-PACIFIC VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 64. ASIA-PACIFIC VANCOMYCIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 65. ASIA-PACIFIC VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 66. ASIA-PACIFIC VANCOMYCIN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 67. AUSTRALIA VANCOMYCIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. AUSTRALIA VANCOMYCIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 69. AUSTRALIA VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 70. AUSTRALIA VANCOMYCIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 71. AUSTRALIA VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 72. CHINA VANCOMYCIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. CHINA VANCOMYCIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 74. CHINA VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 75. CHINA VANCOMYCIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 76. CHINA VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 77. INDIA VANCOMYCIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. INDIA VANCOMYCIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 79. INDIA VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 80. INDIA VANCOMYCIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 81. INDIA VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 82. INDONESIA VANCOMYCIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. INDONESIA VANCOMYCIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 84. INDONESIA VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 85. INDONESIA VANCOMYCIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 86. INDONESIA VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 87. JAPAN VANCOMYCIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. JAPAN VANCOMYCIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 89. JAPAN VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 90. JAPAN VANCOMYCIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 91. JAPAN VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 92. MALAYSIA VANCOMYCIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. MALAYSIA VANCOMYCIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 94. MALAYSIA VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 95. MALAYSIA VANCOMYCIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 96. MALAYSIA VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 97. PHILIPPINES VANCOMYCIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. PHILIPPINES VANCOMYCIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 99. PHILIPPINES VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 100. PHILIPPINES VANCOMYCIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 101. PHILIPPINES VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 102. SINGAPORE VANCOMYCIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. SINGAPORE VANCOMYCIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 104. SINGAPORE VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 105. SINGAPORE VANCOMYCIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 106. SINGAPORE VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 107. SOUTH KOREA VANCOMYCIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. SOUTH KOREA VANCOMYCIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 109. SOUTH KOREA VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 110. SOUTH KOREA VANCOMYCIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 111. SOUTH KOREA VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 112. TAIWAN VANCOMYCIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. TAIWAN VANCOMYCIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 114. TAIWAN VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 115. TAIWAN VANCOMYCIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 116. TAIWAN VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 117. THAILAND VANCOMYCIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. THAILAND VANCOMYCIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 119. THAILAND VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 120. THAILAND VANCOMYCIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 121. THAILAND VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 122. VIETNAM VANCOMYCIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. VIETNAM VANCOMYCIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 124. VIETNAM VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 125. VIETNAM VANCOMYCIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 126. VIETNAM VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA VANCOMYCIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA VANCOMYCIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA VANCOMYCIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA VANCOMYCIN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 133. DENMARK VANCOMYCIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. DENMARK VANCOMYCIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 135. DENMARK VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 136. DENMARK VANCOMYCIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 137. DENMARK VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 138. EGYPT VANCOMYCIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. EGYPT VANCOMYCIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 140. EGYPT VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 141. EGYPT VANCOMYCIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 142. EGYPT VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 143. FINLAND VANCOMYCIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 144. FINLAND VANCOMYCIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 145. FINLAND VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 146. FINLAND VANCOMYCIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 147. FINLAND VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 148. FRANCE VANCOMYCIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 149. FRANCE VANCOMYCIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 150. FRANCE VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 151. FRANCE VANCOMYCIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 152. FRANCE VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 153. GERMANY VANCOMYCIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 154. GERMANY VANCOMYCIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 155. GERMANY VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 156. GERMANY VANCOMYCIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 157. GERMANY VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 158. ISRAEL VANCOMYCIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 159. ISRAEL VANCOMYCIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 160. ISRAEL VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 161. ISRAEL VANCOMYCIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 162. ISRAEL VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 163. ITALY VANCOMYCIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 164. ITALY VANCOMYCIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 165. ITALY VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 166. ITALY VANCOMYCIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 167. ITALY VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 168. NETHERLANDS VANCOMYCIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 169. NETHERLANDS VANCOMYCIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 170. NETHERLANDS VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 171. NETHERLANDS VANCOMYCIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 172. NETHERLANDS VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 173. NIGERIA VANCOMYCIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 174. NIGERIA VANCOMYCIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 175. NIGERIA VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 176. NIGERIA VANCOMYCIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 177. NIGERIA VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 178. NORWAY VANCOMYCIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 179. NORWAY VANCOMYCIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 180. NORWAY VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 181. NORWAY VANCOMYCIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 182. NORWAY VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 183. POLAND VANCOMYCIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 184. POLAND VANCOMYCIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 185. POLAND VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 186. POLAND VANCOMYCIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 187. POLAND VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 188. QATAR VANCOMYCIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 189. QATAR VANCOMYCIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 190. QATAR VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 191. QATAR VANCOMYCIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 192. QATAR VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 193. RUSSIA VANCOMYCIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 194. RUSSIA VANCOMYCIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 195. RUSSIA VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 196. RUSSIA VANCOMYCIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 197. RUSSIA VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 198. SAUDI ARABIA VANCOMYCIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 199. SAUDI ARABIA VANCOMYCIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 200. SAUDI ARABIA VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 201. SAUDI ARABIA VANCOMYCIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 202. SAUDI ARABIA VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 203. SOUTH AFRICA VANCOMYCIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 204. SOUTH AFRICA VANCOMYCIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 205. SOUTH AFRICA VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 206. SOUTH AFRICA VANCOMYCIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 207. SOUTH AFRICA VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 208. SPAIN VANCOMYCIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 209. SPAIN VANCOMYCIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 210. SPAIN VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 211. SPAIN VANCOMYCIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 212. SPAIN VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 213. SWEDEN VANCOMYCIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 214. SWEDEN VANCOMYCIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 215. SWEDEN VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 216. SWEDEN VANCOMYCIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 217. SWEDEN VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 218. SWITZERLAND VANCOMYCIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 219. SWITZERLAND VANCOMYCIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 220. SWITZERLAND VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 221. SWITZERLAND VANCOMYCIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 222. SWITZERLAND VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 223. TURKEY VANCOMYCIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 224. TURKEY VANCOMYCIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 225. TURKEY VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 226. TURKEY VANCOMYCIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 227. TURKEY VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 228. UNITED ARAB EMIRATES VANCOMYCIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 229. UNITED ARAB EMIRATES VANCOMYCIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 230. UNITED ARAB EMIRATES VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 231. UNITED ARAB EMIRATES VANCOMYCIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 232. UNITED ARAB EMIRATES VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 233. UNITED KINGDOM VANCOMYCIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 234. UNITED KINGDOM VANCOMYCIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 235. UNITED KINGDOM VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 236. UNITED KINGDOM VANCOMYCIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 237. UNITED KINGDOM VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 238. VANCOMYCIN MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 239. VANCOMYCIN MARKET, FPNV POSITIONING MATRIX, 2023